Back to Improving outcomes in patients with newly-diagnosed secondary AML
Improving outcomes in patients with newly-diagnosed secondary AML

Improving outcomes in patients with newly-diagnosed secondary AML

Jazz Pharmaceuticals Webinar

Register for this 1-hour webinar to gain a better understanding of therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), and treatment with VYXEOS® (daunorubicin and cytarabine).

Learning Objectives

-Understand the overall prognosis of AML, specifically t-AML or AML-MRC

-Discuss the proposed mechanism of action of VYXEOS for injection

-Examine the phase 3 trial which evaluated the efficacy and safety of VYXEOS

-Review VYXEOS dosing and administration

Product Details

Improving outcomes in patients with newly-diagnosed secondary AML
  • List Price: Free